Clinical application of high throughput molecular screening techniques for pharmacogenomics

Pharmacogenomics and Personalized Medicine

Volumn 4, Issue 1, 2011, Pages 109-121

  Wiita, Arun P ^a   Schrijver, Iris ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Clinical laboratories; High throughput; Mutation; Pharmacogenomics

Indexed keywords

ABACAVIR; CARBAMAZEPINE; CLOPIDOGREL; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; ERLOTINIB; GEFITINIB; IRINOTECAN; MERCAPTOPURINE; PEGINTERFERON ALPHA; RIBAVIRIN; VEMURAFENIB; WARFARIN;

ACCURACY; ARTERY THROMBOSIS; BONE MARROW SUPPRESSION; BRAF GENE; CLINICAL EFFECTIVENESS; COLORECTAL CANCER; CYP2C19 GENE; CYP2C9 GENE; CYP2D6 GENE; DNA HYBRIDIZATION; DNA MICROARRAY; DNA SEQUENCE; DRUG EFFECT; DRUG EXCRETION; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG METABOLISM; DRUG RESPONSE; EGFR GENE; GASTROINTESTINAL TOXICITY; GENE; GENE TARGETING; GENETIC ALGORITHM; GENETIC IDENTIFICATION; GENETIC MARKER; GENETIC SCREENING; GENETIC VARIABILITY; GENOTYPE; HEPATITIS C; HIGH THROUGHPUT SCREENING; HLA B GENE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IL28B GENE; LABORATORY TEST; LUNG NON SMALL CELL CANCER; LYMPHATIC LEUKEMIA; MOLECULARLY TARGETED THERAPY; MUTATIONAL ANALYSIS; MYELOMA; NEUTROPENIA; OLIGONUCLEOTIDE PROBE; ONCOGENE K RAS; PHARMACOGENOMICS; PROCESS MONITORING; REAL TIME POLYMERASE CHAIN REACTION; REVIEW; RHEUMATIC DISEASE; SINGLE NUCLEOTIDE POLYMORPHISM; SOLID TUMOR; THIOPURINE METHYLTRANSFERASE GENE; THROMBOSIS; UGT1A1 GENE; VALIDATION PROCESS; VITAMIN K EPOXIDE REDUCTASE GENE;

EID: 83755196521     PISSN: None     EISSN: 11787066     Source Type: Journal    
DOI: None     Document Type: Review

References (91)

1. Altshuler DL, Durbin RM, Abecasis GR, et al. A map of human genome variation from population-scale sequencing. Nature. 2010;467(7319): 1061-1073.
2. Frazer KA, Ballinger DG, Cox DR, et al. A second generation human haplotype map of over 3.1 million SNPs. Nature. 2007;449(7164): 851-861.
3. Chanock SJ, Manolio T, Boehnke M, et al. Replicating genotype-phenotype associations. Nature. 2007;447(7145):655-660.
4. Sim SC, Ingelman-Sundberg M. Pharmacogenomic biomarkers: new tools in current and future drug therapy. Trends Pharmacol Sci. 2011; 32(2):72-81.
5. Lee SY, McLeod HL. Pharmacogenetic tests in cancer chemotherapy: what physicians should know for clinical application. J Pathol. 2011; 223(1):15-27.
6. Wang L, McLeod HL, Weinshilboum RM. Genomics and drug response. N Engl J Med. 2011;364(12):1144-1153.
7. Hoggatt J. Personalized medicine-trends in molecular diagnostics: exponential growth expected in the next ten years. Mol Diagn Ther. 2011;15(1):53-55.
8. McCarroll SA, Kuruvilla FG, Korn JM, et al. Integrated detection and population-genetic analysis of SNPs and copy number variation. Nat Genet. 2008;40(10):1166-1174.
9. Fan JB, Gunderson KL, Bibikova M, et al. Illumina universal bead arrays. Methods Enzymol. 2006;410:57-73.
10. Heller T, Kirchheiner J, Armstrong VW, et al. Ampli Chip CYP450 Gene Chip: a new gene chip that allows rapid and accurate CYP2D6 genotyping. Ther Drug Monit. 2006;28(5):673-677.
11. Burmester JK, Sedova M, Shapero MH, Mansfield E. DMET microarray technology for pharmacogenomics-based personalized medicine. Methods Mol Biol. 2010;632:99-124.
12. Podder M, Ruan J, Tripp BW, Chu ZE, Tebbutt SJ. Robust SNP genotyping by multiplex PCR and arrayed primer extension. BMC Med Genomics. 2008;1:5.
13. Schrijver I, Oitmaa E, Metspalu A, Gardner P. Genotyping microarray for the detection of more than 200 CFTR mutations in ethnically diverse populations. J Mol Diagn. 2005;7(3):375-387.
14. Vairavan R. AutoGenomics, Inc. Pharmacogenomics. 2004;5(5): 585-588.
15. Dunbar SA. Applications of Luminex xMAP technology for rapid, high-throughput multiplexed nucleic acid detection. Clin Chim Acta. 2006;363(1-2):71-82.
16. Bao YP, Huber M, Wei TF, Marla SS, Storhoff JJ, Muller UR. SNP identification in unamplified human genomic DNA with gold nanoparticle probes. Nucleic Acids Res. 2005;33(2):e15.
17. Umek RM, Lin SW, Vielmetter J, et al. Electronic detection of nucleic acids: a versatile platform for molecular diagnostics. J Mol Diagn. 2001; 3(2):74-84.
18. Pettersson E, Lundeberg J, Ahmadian A. Generations of sequencing technologies. Genomics. 2009;93(2):105-111.
19. Fakhrai-Rad H, Pourmand N, Ronaghi M. Pyrosequencing: an accurate detection platform for single nucleotide polymorphisms. Hum Mutat. 2002;19(5):479-485.
20. Wheeler DA, Srinivasan M, Egholm M, et al. The complete genome of an individual by massively parallel DNA sequencing. Nature. 2008;452(7189):872-876.
21. Fujimoto A, Nakagawa H, Hosono N, et al. Whole-genome sequencing and comprehensive variant analysis of a Japanese individual using massively parallel sequencing. Nat Genet. 2010;42(11):931-936.
22. Metzker ML. Sequencing technologies - the next generation. Nat Rev Genet. 2010;11(1):31-46.
23. Welch JS, Westervelt P, Ding L, et al. Use of whole-genome sequencing to diagnose a cryptic fusion oncogene. JAMA. 2011;305(15): 1577-1584.
24. Ashley EA, Butte AJ, Wheeler MT, et al. Clinical assessment incorporating a personal genome. Lancet. 2010;375(9725):1525-1535.
25. Margulies M, Egholm M, Altman WE, et al. Genome sequencing in microfabricated high-density picolitre reactors. Nature. 2005;437(7057): 376-380.
26. Bentley DR, Balasubramanian S, Swerdlow HP, et al. Accurate whole human genome sequencing using reversible terminator chemistry. Nature. 2008;456(7218):53-59.
27. Livak KJ. Allelic discrimination using fluorogenic probes and the 5' nuclease assay. Genet Anal. 1999;14(5-6):143-149.
28. Wittwer CT, Herrmann MG, Gundry CN, Elenitoba-Johnson KS. Real-time multiplex PCR assays. Methods. 2001;25(4):430-442.
29. Lyon E, Wittwer CT. Light Cycler technology in molecular diagnostics. J Mol Diagn. 2009;11(2):93-101.
30. El Helali N, Nguyen JC, Ly A, Giovangrandi Y, Trinquart L. Diagnostic accuracy of a rapid real-time polymerase chain reaction assay for universal intrapartum group B streptococcus screening. Clin Infect Dis. 2009;49(3):417-423.
31. Boehme CC, Nabeta P, Hillemann D, et al. Rapid molecular detection of tuberculosis and rifampin resistance. N Engl J Med. 2010;363(11): 1005-1015.
32. Gibson NJ. The use of real-time PCR methods in DNA sequence variation analysis. Clin Chim Acta. 2006;363(1/2):32-47.
33. Little DP, Braun A, O'Donnell MJ, Koster H. Mass spectrometry from miniaturized arrays for full comparative DNA analysis. Nat Med. 1997; 3(12):1413-1416.
34. Oeth P, del Mistro G, Marnellos G, Shi T, van den Boom D. Qualitative and quantitative genotyping using single base primer extension coupled with matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MassARRAY). Methods Mol Biol. 2009;578:307-343.
35. Wright WT, Heggarty SV, Young IS, et al. Multiplex MassARRAY spectrometry (iPLEX) produces a fast and economical test for 56 familial hypercholesterolaemia-causing mutations. Clin Genet. 2008;74(5):463-468.
36. Syvanen AC. Accessing genetic variation: genotyping single nucleotide polymorphisms. Nat Rev Genet. 2001;2(12):930-942.
37. Pourzand C, Cerutti P. Genotypic mutation analysis by RFLP/PCR. Mutat Res. 1993;288(1):113-121.
38. Newton CR, Graham A, Heptinstall LE, et al. Analysis of any point mutation in DNA. The amplification refractory mutation system (ARMS). Nucleic Acids Res. 1989;17(7):2503-2516.
39. Lyamichev V, Mast AL, Hall JG, et al. Polymorphism identification and quantitative detection of genomic DNA by invasive cleavage of oligonucleotide probes. Nat Biotechnol. 1999;17(3):292-296.
40. Riedlinger J, Beqaj SH, Milish MA, et al. Multicenter evaluation of the BD Max GBS assay for detection of group B streptococci in prenatal vaginal and rectal screening swab specimens from pregnant women. J Clin Microbiol. 2010;48(11):4239-4241.
41. Little S. FDA regulations and novel molecular diagnostic tests. Clin Lab Int. 2006;7:48-49.
42. US Food and Drug Administration. Table of pharmacogenomic biomarkers in drug labels. Updated July 27, 2011. Available from: http://www.fda.gov/drugs/scienceresearch/researchareas/pharmacogenetics/ucm083378.htm. Accessed May 2, 2011.
43. US Food and Drug Administration. IVD: in vitro diagnostic product database. Updated 29 July, 2011. Available from: http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfivd/index.cfm. Accessed May 2, 2011.
44. Sconce EA, Khan TI, Wynne HA, et al. The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. Blood. 2005;106(7):2329-2333.
45. Lanham KJ, Oestreich JH, Dunn SP, Steinhubl SR. Impact of genetic polymorphisms on clinical response to antithrombotics. Pharmacogenomics Pers Med. 2010;3:87-99.
46. Gong IY, Tirona RG, Schwarz UI, et al. Prospective evaluation of a pharmacogenetics-guided warfarin loading and maintenance dose regimen for initiation of therapy. Blood. July 1, 2011. [Epub ahead of print.]
47. Wadelius M, Chen LY, Eriksson N, et al. Association of warfarin dose with genes involved in its action and metabolism. Hum Genet. 2007; 121(1):23-34.
48. Nanosphere. Verigene Warfarin Metabolism Nucleic Acid Test (IVD). 2010. Available from: http://www.nanosphere.us/verigenewarfarinmetabolismnucleicacidtest_4472.aspx. Accessed May 23, 2011.
49. GenMark Dx. ESensor® Warfarin Sensitivity Test. 2010. Available from: http://www.genmarkdx.com/products/reagents/warfarin.php. Accessed May 23, 2011.
50. van Schie RM, Wadelius MI, Kamali F, et al. Genotype-guided dosing of coumarin derivatives: the European pharmacogenetics of anticoagulant therapy (EU-PACT) trial design. Pharmacogenomics. 2009;10(10):1687-1695.
51. Maurice CB, Barua PK, Simses D, Smith P, Howe JG, Stack G. Comparison of assay systems for warfarin-related CYP2C9 and VKORC1 genotyping. Clin Chim Acta. 2010;411(13/14):947-954.
52. Langley MR, Booker JK, Evans JP, McLeod HL, Weck KE. Validation of clinical testing for warfarin sensitivity: comparison of CYP2C9-VKORC1 genotyping assays and warfarin-dosing algorithms. J Mol Diagn. 2009;11(3):216-225.
53. Mega JL, Simon T, Collet JP, et al. Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis. JAMA. 2010; 304(16):1821-1830.
54. Simon T, Verstuyft C, Mary-Krause M, et al. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med. 2009; 360(4):363-375.
55. Ellis KJ, Stouffer GA, McLeod HL, Lee CR. Clopidogrel pharmacogenomics and risk of inadequate platelet inhibition: US FDA recommendations. Pharmacogenomics. 2009;10(11):1799-1817.
56. Pare G, Mehta SR, Yusuf S, et al. Effects of CYP2C19 genotype on outcomes of clopidogrel treatment. N Engl J Med. 2010;363(18): 1704-1714.
57. Swen JJ, Nijenhuis M, de Boer A, et al. Pharmacogenetics: from bench to byte - an update of guidelines. Clin Pharmacol Ther. 2011;89(5): 662-673.
58. Ned RM. Genetic testing for CYP450 polymorphisms to predict response to clopidgrel: current evidence and test availability. Application: pharmacogenomics. PLoS Curr. 2010;2:RRN1180.
59. Lee CC, McMillin GA, Babic N, Melis R, Yeo KT. Evaluation of a CYP2C19 genotype panel on the GenMark eSensor(R) platform and the comparison to the Autogenomics Infiniti and Luminex CYP2C19 panels. Clin Chim Acta. 2011;412(11/12):1133-1137.
60. Ingelman-Sundberg M. Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity. Pharmacogenomics J. 2005;5(1):6-13.
61. de Gregori M, Allegri M, de Gregori S, et al. How and why to screen for CYP2D6 interindividual variability in patients under pharmacological treatments. Curr Drug Metab. 2010;11(3):276-282.
62. Brockmoller J, Kirchheiner J, Schmider J, et al. The impact of the CYP2D6 polymorphism on haloperidol pharmacokinetics and on the outcome of haloperidol treatment. Clin Pharmacol Ther. 2002; 72(4):438-452.
63. de Leon J, Susce MT, Pan RM, Fairchild M, Koch WH, Wedlund PJ. The CYP2D6 poor metabolizer phenotype may be associated with risperidone adverse drug reactions and discontinuation. J Clin Psychiatry. 2005;66(1):15-27.
64. Hoskins JM, Carey LA, McLeod HL. CYP2D6 and tamoxifen: DNA matters in breast cancer. Nat Rev Cancer. 2009;9(8):576-586.
65. Fleeman N, Dundar Y, Dickson R, et al. Cytochrome P450 testing for prescribing antipsychotics in adults with schizophrenia: systematic review and meta-analyses. Pharmacogenomics J. 2011;11(1):1-14.
66. Innocenti F, Undevia SD, Iyer L, et al. Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J Clin Oncol. 2004;22(8):1382-1388.
67. Rouits E, Boisdron-Celle M, Dumont A, Guerin O, Morel A, Gamelin E. Relevance of different UGT1A1 polymorphisms in irinotecan-induced toxicity: a molecular and clinical study of 75 patients. Clin Cancer Res. 2004;10(15):5151-5159.
68. Marsh S, Hoskins JM. Irinotecan pharmacogenomics. Pharmacogenomics. 2010;11(7):1003-1010.
69. Ford LT, Berg JD. Thiopurine S-methyltransferase (TPMT) assessment prior to starting thiopurine drug treatment; a pharmacogenomic test whose time has come. J Clin Pathol. 2010;63(4):288-295.
70. Zhou S. Clinical pharmacogenomics of thiopurine S-methyltransferase. Curr Clin Pharmacol. 2006;1(1):119-128.
71. Mallal S, Nolan D, Witt C, et al. Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet. 2002;359(9308): 727-732.
72. US Food and Drug Administration. July 24, 2008. Information on abacavir (marketed as Ziagen) and abacavir-containing medications. Available from: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm094302.htm. Accessed May 23, 2011.
73. Mallal S, Phillips E, Carosi G, et al. HLA-B*5701 screening for hypersensitivity to abacavir. N Engl J Med. 2008;358(6):568-579.
74. Saag M, Balu R, Phillips E, et al. High sensitivity of human leukocyte antigen-b*5701 as a marker for immunologically confirmed abacavir hypersensitivity in white and black patients. Clin Infect Dis. 2008; 46(7):1111-1118.
75. Franciotta D, Kwan P, Perucca E. Genetic basis for idiosyncratic reactions to antiepileptic drugs. Curr Opin Neurol. 2009;22(2):144-149.
76. Chung WH, Hung SI, Hong HS, et al. Medical genetics: a marker for Stevens-Johnson syndrome. Nature. 2004;428(6982):486.
77. US Food and Drug Administration. January 31, 2008. Information on carbamazepine (marketed as Carbatrol, Equetro, Tegretol, and generics) with FDA alerts. Available from: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm107834.htm. Accessed May 23, 2011.
78. Ahlenstiel G, Booth DR, George J. IL28B in hepatitis C virus infection: translating pharmacogenomics into clinical practice. J Gastroenterol. 2010;45(9):903-910.
79. Rauch A, Kutalik Z, Descombes P, et al. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology. 2010;138(4):1338-1345.
80. Tanaka Y, Nishida N, Sugiyama M, et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet. 2009;41(10):1105-1109.
81. Ge D, Fellay J, Thompson AJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature. 2009; 461(7262):399-401.
82. Thomas DL, Thio CL, Martin MP, et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature. 2009;461(7265): 798-801.
83. Li J, Wang L, Mamon H, Kulke MH, Berbeco R, Makrigiorgos GM. Replacing PCR with COLD-PCR enriches variant DNA sequences and redefines the sensitivity of genetic testing. Nat Med. 2008;14(5): 579-584.
84. Gazdar AF. Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors. Oncogene. 2009;28 Suppl 1:S24-S31.
85. Vakiani E, Solit DB. KRAS and BRAF: drug targets and predictive biomarkers. J Pathol. 2011;223(2):219-229.
86. Flaherty KT, Puzanov I, Kim KB, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med. 2010;363(9):809-819.
87. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417(6892):949-954.
88. Dias-Santagata D, Akhavanfard S, David SS, et al. Rapid targeted mutational analysis of human tumours: a clinical platform to guide personalized cancer medicine. EMBO Mol Med. 2010;2(5):146-158.
89. Kim S, Misra A. SNP genotyping: technologies and biomedical applications. Annu Rev Biomed Eng. 2007;9:289-320.
90. Wu AHB, Babic N, Yeo KTJ. Implementation of pharmacogenomics into the clinical practice of therapeutics: issues for the clinician and the laboratorian. Per Med. 2009;6(3):315-327.
91. Kiechle FL, Holland CA. Point-of-care testing and molecular diagnostics: miniaturization required. Clin Lab Med. 2009;29(3):555-560.